참고문헌
- Alvarez RD, To A, Boots LR, et al (1987). CA125 assay serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol, 26, 284-9 https://doi.org/10.1016/0090-8258(87)90019-9
- Bae HS, Kim HJ, Hong JH, et al (2014). Obesity and epithelial ovarian cancer survival: a systematic review and metaanalysis. J Ovarian Res, 7, 41 https://doi.org/10.1186/1757-2215-7-41
- Buller RE (2002). Preoperative CA125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol, 100, 59-64
- Chen Y , Zhang L, Liu WX, Xiang-Yu Liu XY (2015). Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev, 16, 933-9 https://doi.org/10.7314/APJCP.2015.16.3.933
- Chen X, Zhang J, Cheng W, et al (2013). CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer. Inter J Gynecol Cancer, 23, 815-22 https://doi.org/10.1097/IGC.0b013e31828f7a24
- Colombo N, Van GT, Parma G, et al (2006). Ovarian cancer. Crit Rev Oncol Hematol, 60, 159-79 https://doi.org/10.1016/j.critrevonc.2006.03.004
- Cooper BC, Sood AK, Davis CS, et al (2002). Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol, 100, 59-64.
- Cruickshank DJ, Fullerton WT, Klopper A (1987). The climical significance of pre-operative serum CA125 in ovarian cancer. Br J Obstet Gynaecol, 94, 692-5 https://doi.org/10.1111/j.1471-0528.1987.tb03177.x
- du Bois A, Reuss A, Pujade-Lauraine E, et al (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 115, 1234-44 https://doi.org/10.1002/cncr.24149
- Gadducci A, Zola P, Landoni F, Maggino T (1995). Serum half-life of CA125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol, 58, 42-7 https://doi.org/10.1006/gyno.1995.1181
- Gupta D, Lis CG (2009). Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. J Ovarian Res, 2, 13 https://doi.org/10.1186/1757-2215-2-13
- Havrilesky LJ, Whitehead CM, Rubatt JM, et al (2008). Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol, 110, 374-82 https://doi.org/10.1016/j.ygyno.2008.04.041
- Hogdall E (2008). Cancer antigen 125 and prognosis. Curr Opin Obstet Gynaecol, 20, 4-8 https://doi.org/10.1097/GCO.0b013e3282f2b124
- Jacobs I, Bast RC (1989). The CA125 tumour-associated antigen: a review of the literature. Hum Reprod, 4, 1-12 https://doi.org/10.1093/humrep/4.suppl_1.1
- Jemal A, Siegel R, Ward E, et al (2008). Cancer Statistics, 2008. CA Cancer J Clin, 58, 71-96 https://doi.org/10.3322/CA.2007.0010
- Lawiki S, Bedkowska GE, Gacuta-Szmitkowski M (2014). The plasma concentration of VEGF, HE-4 and CA125 as a new biomarkers panel in different stages and subtypes of epithelial ovarian tumors. J Ovar Res, 6, 45
- Liu XH, Ya-Nan Man YN, Wu XZ (2014). Recurrence season impacts the survival of epithelial ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1627-32 https://doi.org/10.7314/APJCP.2014.15.4.1627
- Makar AP, Kristensen GB, Kaern J, et al (1992). Prognostic value of pre and postoperative serum CA125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol, 79, 1002 -10
- Menon U, Jacobs IJ (2001). Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol, 13, 61-4 https://doi.org/10.1097/00001703-200102000-00009
- Moebus V (1988). Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol, 3, 251-8.
- Nagele F, Petru E, Medl M, et al (1995). Preoperative CA125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol, 86, 259-64 https://doi.org/10.1016/0029-7844(95)00126-C
- Nustad K, Bast RC Jr, Brien TJ, et al (1996). Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. international society for oncodevelopmental biology and medicine. Tumour Biol, 17, 196-219 https://doi.org/10.1159/000217982
- Osman N, O'Leary N, Mulcahy E, et al (2008). Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J, 101, 245-7
- Parker D, Patel K, Alred EJ, et al (1988). CA125 and survival in ovarian cancer. J Royal Soc Med, 82, 22.
- Petri AL, Hogdall E, Christensen IJ, et al (2006): Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS, 114, 359-63 https://doi.org/10.1111/j.1600-0463.2006.apm_397.x
- Pradjatmo H (2015). Methylation status and expression of brca2 in epithelial ovarian cancers in indonesia. Asian Pac J Cancer Prev, 16, 8599-604
- Pongsanon K, Benjapibal M, Ruengkhachorn I (2011). Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinumbased chemotherapy. Asian Pac J Cancer Prev, 12, 131-6
- Rapkiewicz AV, Espina V, Petriconin EF, Liotta LA (2004). Biomarkers of ovarian tumours. Eur J Cancer, 40, 2604-12 https://doi.org/10.1016/j.ejca.2004.05.021
- Redman CWE, Blackledge GR, Kelly K, et al (1990). Early CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer, 26, 593-6 https://doi.org/10.1016/0277-5379(90)90085-8
- Rustin GJ, van der Burg ME (2009). A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol, 27, 1 https://doi.org/10.1200/JCO.2009.22.1515
- Rustin G, van der Burg M, Griffin C., et al (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/ EORTC 55955): a randomized trial. Lancet, 376, 1155-63 https://doi.org/10.1016/S0140-6736(10)61268-8
- Sarwar SCM, Siddiqui N, Khokhar RA, Badar F (2006) Epithelial ovarian cancer at a cancer hospital in a developing country. Asian Pac J Cancer Prev, 7, 595-8
- Sevelda P, Schemper M, Spona J (1989). CA125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynaecol, 161, 1213-6. https://doi.org/10.1016/0002-9378(89)90668-6
- Siegel RL, Miller KD, Jemal A, (2015). Cancer statistics, 2015. CA Cancer J Clin, 65, 5-29 https://doi.org/10.3322/caac.21254
- Sihombing M, Sirait AM (2007). Angka ketahanan hidup penderita kanker ovarium di RS Dr. Ciptomangunkusumo, Jakarta. Maj Kedok Indon, 57, 346-52
- Tang A, Kondalsamy-Chennakesavan S, Ngan H, et al (2012). Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801). Gynecol Oncol, 126, 36-40 https://doi.org/10.1016/j.ygyno.2012.02.031
- Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003). Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol, 101, 885-91
- Urban N (2003). Specific keynote: Ovarian cancer risk assessment and the potential for early detection. Gynecol Oncol, 88, 75-9 https://doi.org/10.1006/gyno.2002.6689
- Verheijen RH, Mensdorff-Pouilly S, van Kamp GJ, Kenemans P (1999). CA125: fundamental and clinical aspects. Semin Cancer Biol, 9, 117-24 https://doi.org/10.1006/scbi.1998.0114
- Whitehouse C, Solomon E (2003). Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in the clinical setting. Gynecol Oncol, 88, 152-7 https://doi.org/10.1006/gyno.2002.6708
피인용 문헌
- Cervical Cancer Markers: Epigenetics and microRNAs vol.49, pp.2, 2018, https://doi.org/10.1093/labmed/lmx080